Logo image of SCNI

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock Fundamental Analysis

NASDAQ:SCNI - Nasdaq - US09073Q3039 - ADR - Currency: USD

2.76  -0.07 (-2.47%)

Fundamental Rating

1

Overall SCNI gets a fundamental rating of 1 out of 10. We evaluated SCNI against 560 industry peers in the Biotechnology industry. SCNI has a bad profitability rating. Also its financial health evaluation is rather negative. SCNI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SCNI had negative earnings in the past year.
SCNI had a negative operating cash flow in the past year.
In the past 5 years SCNI always reported negative net income.
In the past 5 years SCNI always reported negative operating cash flow.
SCNI Yearly Net Income VS EBIT VS OCF VS FCFSCNI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

SCNI has a Return On Assets of 20.69%. This is amongst the best in the industry. SCNI outperforms 97.33% of its industry peers.
SCNI has a Return On Equity of 25.36%. This is amongst the best in the industry. SCNI outperforms 96.98% of its industry peers.
Industry RankSector Rank
ROA 20.69%
ROE 25.36%
ROIC N/A
ROA(3y)-32.4%
ROA(5y)-39.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCNI Yearly ROA, ROE, ROICSCNI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300

1.3 Margins

SCNI has a Profit Margin of 561.28%. This is amongst the best in the industry. SCNI outperforms 99.64% of its industry peers.
SCNI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 561.28%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCNI Yearly Profit, Operating, Gross MarginsSCNI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for SCNI has been increased compared to 1 year ago.
Compared to 5 years ago, SCNI has more shares outstanding
Compared to 1 year ago, SCNI has a worse debt to assets ratio.
SCNI Yearly Shares OutstandingSCNI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100K 200K 300K 400K 500K
SCNI Yearly Total Debt VS Total AssetsSCNI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -15.14, we must say that SCNI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -15.14, SCNI is not doing good in the industry: 80.61% of the companies in the same industry are doing better.
SCNI has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
SCNI has a worse Debt to Equity ratio (0.03) than 60.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -15.14
ROIC/WACCN/A
WACCN/A
SCNI Yearly LT Debt VS Equity VS FCFSCNI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.16 indicates that SCNI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.16, SCNI is not doing good in the industry: 86.65% of the companies in the same industry are doing better.
SCNI has a Quick Ratio of 1.16. This is a normal value and indicates that SCNI is financially healthy and should not expect problems in meeting its short term obligations.
SCNI has a worse Quick ratio (1.16) than 85.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
SCNI Yearly Current Assets VS Current LiabilitesSCNI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

SCNI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.00%, which is quite impressive.
EPS 1Y (TTM)109%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNI Yearly EPS VS EstimatesSCNI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCNI. In the last year negative earnings were reported.
Also next year SCNI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCNI Price Earnings VS Forward Price EarningsSCNI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNI Per share dataSCNI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SCNI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCINAI IMMUNOTHERAPEUTICS LT

NASDAQ:SCNI (5/23/2025, 8:54:54 PM)

2.76

-0.07 (-2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2024-05-15/amc
Earnings (Next)N/A N/A
Inst Owners13.75%
Inst Owner Change-33.97%
Ins Owners7.62%
Ins Owner ChangeN/A
Market Cap2.58M
Analysts82.86
Price Target714 (25769.57%)
Short Float %0.68%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.7
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-18.7
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-7.21
FCFYN/A
OCF(TTM)-6.94
OCFYN/A
SpS0.48
BVpS10.71
TBVpS10.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 25.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 561.28%
GM N/A
FCFM N/A
ROA(3y)-32.4%
ROA(5y)-39.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.94%
Cap/Sales 54.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -15.14
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)96.83%
Cap/Depr(5y)198.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y98.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.6%
OCF growth 3YN/A
OCF growth 5YN/A